Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study

Publication | Open Access

DOI Full Paper Access

119

Citations

References

2024

Year

Zhi‐Cheng Jin, Jian-Jia Chen, Xiaoli Zhu, Xuhua Duan, Yujing Xin, Bin‐Yan Zhong, Jinzhang Chen, Jun Tie, Kangshun Zhu, Lan Zhang,

EClinicalMedicine

MedicineImmune Checkpoint InhibitorsImmunologyImmune Checkpoint InhibitorTransarterial ChemoembolizationLiver CancerImmunotherapyOncologyRadiation OncologyTumor MicroenvironmentHepatocellular CarcinomaAdvanced Hepatocellular Carcinoma